NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ARTHEx Biotech

ARTHEx Biotech

Private
ValenciaHealthcare & Life Scienceshttps://www.arthexbiotech.com/

Last Round

Series B

Sep 17, 2025

Total Funding Raised

$95M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ARTHEx Biotech is a biotechnology company that develops targeted RNA medicines for rare genetic neuromuscular disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

RNA therapyantisense oligonucleotideMyotonic Dystrophy Type 1DM1ASO therapyrare disease therapyclinical stage biotechmicroRNA inhibitororphan druggene silencingneuromuscular disease therapyoligonucleotide deliveryMBNL proteinFDA Fast TrackCNS therapydrug delivery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ARTHEx Biotech Comps

Public and private peers based on sector, stage, and business model.

ARTHEx Biotech comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ARTHEx Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 17, 2025
SeedJul 23, 2020

Key People

Founding team and executive leadership

beatriz llamusi

CEO And Co-founder

Founding Team

Frederic LEGROS

Chief Executive Officer, Executive Chairman

Executive Team

ARTHEx Biotech Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 67% MoM.

  • Nov 6, 2025

    Monthly visitors grew 49% MoM, reaching 3K.

ARTHEx Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ARTHEx Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ARTHEx Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersValencia
Employee Range29
Year Founded2019
Last FundingSep 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.